News and Announcements
Actinogen Medical Presenting at the BIO International Conversation in San Diego
- Published June 19, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Actinogen Medical (ASX: ACW) is pleased to announce that the Company‘s CEO, Dr. Bill Ketelbey, is leading the Actinogen team and presenting at the BIO International Convention in San Diego in June 2017. This follows the successful initiation of XanADu, its Phase II trial of Xanamem in Alzheimer’s Disease, and the progress made towards the commencement of a second Phase II trial of Xanamem in Diabetes Cognitive Impairment.
KEY TAKEAWAYS:
- Actinogen Medical presenting at BIO International Convention, the world’s largest and most prestigious biotechnology convention in San Diego, this month.
- BIO International attracts the global biotech industry to network on new opportunities and partnerships.
- Ideal forum to showcase Actinogen Medical and Xanamem, including the successful initiation of our XanADu Alzheimer’s Disease trial and plans to initiate a second Phase II trial of Xanamem in Diabetes Cognitive Impairment.
The BIO International Convention, hosted by the Biotechnology Innovation Organisation (BIO), is the largest global convention for the biotechnology industry and attracts the biggest and best organisations in biotech to network on new opportunities and potential partnerships. Participation at BIO offers Actinogen Medical unparalleled networking opportunities to showcase Xanamem and the quality research that supports its development.
To view the company’s BIO presentation please click the more information button below.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
